Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5055965 | 1.00 | BACE1 (0.65) | BACE1CTSD | |
| SCHEMBL5055960 | 0.92 | BACE1 (0.77) | BACE1CTSD | |
| SCHEMBL6510791 | 0.92 | BACE1 (0.67) | BACE1CTSD | |
| SCHEMBL5061759 | 0.92 | BACE1 (0.67) | BACE1CTSD | |
| SCHEMBL6699732 | 0.91 | BACE1 (0.69) | BACE1CTSD | |
| SCHEMBL6699730 | 0.91 | BACE1 (0.69) | BACE1CTSD | |
| SCHEMBL6704127 | 0.90 | BACE1 (0.68) | BACE1CTSD | |
| SCHEMBL6704129 | 0.90 | BACE1 (0.68) | BACE1CTSD | |
| SCHEMBL6699044 | 0.90 | BACE1 (0.72) | BACE1CTSD | |
| SCHEMBL6699048 | 0.90 | BACE1 (0.72) | BACE1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040171881-A1 | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives | PHARMACIA & UPJOHN COMPANY | 2004-09-02 | — | — | US | claimed |
| US-20080207696-A1 | Phenacyl 2-Hydroxy-3-Diaminoalkanes | AQUINO JOSE | 2008-08-28 | — | — | US | disclosed |
| US-20050054690-A1 | Phenacyl 2-hydroxy-3-diaminoalkanes | PHARMACIA & UPJOHN COMPANY | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171881-A1 | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives | BACE1, BACE2, PSEN1 | BACE1 1/4885CTSD 249/4885 |
| US-20050054690-A1 | Phenacyl 2-hydroxy-3-diaminoalkanes | APP, PSEN1, BACE2 | BACE1 4/4885CTSD 392/4885 |
| US-20080207696-A1 | Phenacyl 2-Hydroxy-3-Diaminoalkanes | APP, PSEN1, BACE2 | BACE1 4/4885CTSD 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.